Genix Pharmaceuticals EBIT

As of the most recent data (April 2026), GENPF shows a EBIT of $-120K. That compares with $63K in the prior-year period — down 284.2% year over year. That is below the sector sector average of $2.6T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GENPF's EBIT is now $-120K (was $63K) — a 284.2% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Genix Pharmaceuticals is outperforming or lagging.

The its sector sector average EBIT is about $2.6T. Genix Pharmaceuticals is at $-120K, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how GENPF stacks up against individual peers as well.

Tracking GENPF's ebit over time shows whether Genix Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $-120K That compares with $63K in the prior-year period — down 284.2% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Genix Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-120K) with ownership activity and broader fundamentals.